Brokers Issue Forecasts for NMRA FY2030 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for Neumora Therapeutics in a report released on Monday, January 26th. HC Wainwright analyst D. Tsao expects that the company will earn $2.02 per share for the year. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01).

Other equities analysts have also issued research reports about the company. Leerink Partners assumed coverage on Neumora Therapeutics in a research note on Monday, January 12th. They set an “outperform” rating and a $8.00 price objective on the stock. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $4.00 to $7.00 in a research report on Monday, December 1st. Needham & Company LLC increased their price objective on Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Stifel Nicolaus lifted their target price on Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Finally, Mizuho set a $6.00 price target on Neumora Therapeutics in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.13.

Neumora Therapeutics Trading Up 4.4%

Shares of Neumora Therapeutics stock opened at $2.13 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85. The stock’s 50 day simple moving average is $2.05 and its 200-day simple moving average is $1.98. The stock has a market cap of $355.90 million, a P/E ratio of -1.45 and a beta of 3.22. Neumora Therapeutics has a 1-year low of $0.61 and a 1-year high of $3.25.

Insider Buying and Selling at Neumora Therapeutics

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 114,703 shares of Neumora Therapeutics stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $2.68, for a total transaction of $307,404.04. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 26.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Legacy Private Trust Co. increased its position in Neumora Therapeutics by 35.7% in the 4th quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock valued at $34,000 after acquiring an additional 5,000 shares during the period. Vanguard Personalized Indexing Management LLC increased its position in shares of Neumora Therapeutics by 10.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock worth $117,000 after acquiring an additional 6,233 shares in the last quarter. Invesco Ltd. raised its position in Neumora Therapeutics by 6.8% during the second quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after acquiring an additional 8,383 shares during the period. CWM LLC increased its stake in Neumora Therapeutics by 41.8% during the second quarter. CWM LLC now owns 35,750 shares of the company’s stock worth $26,000 after acquiring an additional 10,537 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Neumora Therapeutics in the 3rd quarter valued at approximately $31,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.